Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

MHLW

- PMLiVE

Early 2013 sees drug filings, launches and approvals in Japan

Includes medicines from Bayer, Takeda, Astellas and Eisai

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

Eliquis and Ryzodeg feature among Japan’s year-end approvals

Actonel and Neupro also given green light

- PMLiVE

Market researchers must become internal consultants

Bayer's Dr Thomas Hein gives his first interview as president of the European Pharmaceutical Market Research Association

- PMLiVE

Swedish approval for Bayer’s long-term contraceptive Jaydess

Country is reference member state for approval under the decentralised EU procedure

- PMLiVE

Boehringer launches COPD awareness drive in Japan

Social media campaign will target male smokers’ wives and daughters

- PMLiVE

Bayer’s eye drug Eylea approved in Europe

Will compete with Novartis' Lucentis in wet AMD

- PMLiVE

Reckitt beats Bayer to acquire nutrition company Schiff

Provides springboard to US consumer health market

- PMLiVE

Bayer’s Xarelto cleared in Europe for pulmonary embolism and DVT prevention

Gives further edge over Boehringer’s anticoagulant Pradaxa

- PMLiVE

Reckitt trumps Bayer with $1.4bn bid for Schiff Nutrition

Could spark bidding war for the consumer health company

- PMLiVE

Xarelto uses extended in US

New FDA approval could be huge sales boost for Bayer's and J&J's anticoagulant

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links